Furthermore, this study identified specific molecules (C16orf54, CCR8, CYTIP, SAMD3 and TBX21) that can be used as predictors of the risk of progression and therapeutic targets for patients with sarcomas. This evidence concerns the gene C16orf54 and sarcoma.